ME/CFS South Australia Inc: The Cortene ME/CFS Drug Trial Begins

ME/CFS SOUTH AUSTRALIA INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 322,
Modbury North,
South Australia 5092

Phone:
1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm
(phone)

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

The Cortene ME/CFS Drug Trial Begins

Thursday 16 August 2018

Cortene used a theoretical exercise to rethink how
ME/CFS occurs to help them determine
if their drug might be a good fit.

The Cortene Chronic Fatigue Syndrome (ME/CFS) Drug Trial Begins

Since February, Health Rising has described the development of a new drug produced for chronic fatigue syndrome (ME/CFS) by a small pharmaceutical company named Cortene in three blogs:

Now it’s time to test the drug! Cortene’s trial has received the go-ahead from both the FDA and the Independent Review Board (IRB) and the trial will commence shortly, with Lucinda Bateman, MD, as the Principal Investigator, Suzanne Vernon, PhD, as Co-Investigator, and assisted by the experienced clinical trials team at the Bateman Horne Center.